[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan E. Dickinson B.Sc., M.B.A.", "age": 57, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 130923, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 52, "title": "Executive VP & COO", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 505212, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 63, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 576657, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 61, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 65, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 50, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie  Cornen", "title": "Vice President of Investor Relations, Communication & Commercial Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Odile  Belzunce", "age": 45, "title": "Vice President of Compliance, IT & Portfolio Management", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.69, "open": 1.7, "dayLow": 1.57, "dayHigh": 1.705, "regularMarketPreviousClose": 1.69, "regularMarketOpen": 1.7, "regularMarketDayLow": 1.57, "regularMarketDayHigh": 1.705, "payoutRatio": 0.0, "beta": 0.566, "forwardPE": -2.6732674, "volume": 29947, "regularMarketVolume": 29947, "averageVolume": 23790, "averageVolume10days": 20950, "averageDailyVolume10Day": 20950, "bid": 1.86, "ask": 1.72, "bidSize": 1, "askSize": 1, "marketCap": 151833968, "fiftyTwoWeekLow": 1.57, "fiftyTwoWeekHigh": 2.63, "allTimeHigh": 11.95, "allTimeLow": 1.29, "priceToSalesTrailing12Months": 12.015984, "fiftyDayAverage": 1.78518, "twoHundredDayAverage": 1.962275, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 116297632, "profitMargins": 0.0, "floatShares": 60330181, "sharesOutstanding": 93724668, "sharesShort": 210405, "sharesShortPriorMonth": 242455, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0022, "heldPercentInsiders": 0.01698, "heldPercentInstitutions": 0.00366, "shortRatio": 10.17, "shortPercentOfFloat": 0.0025, "impliedSharesOutstanding": 93724668, "bookValue": 0.0659036, "priceToBook": 24.58136, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -46051000, "trailingEps": -0.65, "forwardEps": -0.606, "enterpriseToRevenue": 9.204, "enterpriseToEbitda": -2.337, "52WeekChange": -0.25641024, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 1.62, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.75, "targetMedianPrice": 6.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 60027000, "totalCashPerShare": 0.651, "ebitda": -49771000, "totalDebt": 27029000, "quickRatio": 2.081, "currentRatio": 2.208, "totalRevenue": 12636000, "debtToEquity": 525.447, "revenuePerShare": 0.15, "returnOnAssets": -0.25922, "returnOnEquity": -2.71367, "grossProfits": -30788000, "freeCashflow": -20764000, "operatingCashflow": -41096000, "revenueGrowth": -0.606, "grossMargins": -2.43653, "ebitdaMargins": 0.0, "operatingMargins": -5.23189, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "regularMarketChange": -0.0700001, "regularMarketDayRange": "1.57 - 1.705", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 23790, "fiftyTwoWeekLowChange": 0.049999952, "fiftyTwoWeekLowChangePercent": 0.0318471, "fiftyTwoWeekRange": "1.57 - 2.63", "fiftyTwoWeekHighChange": -1.0100001, "fiftyTwoWeekHighChangePercent": -0.38403043, "fiftyTwoWeekChangePercent": -25.641024, "earningsTimestamp": 1774531800, "earningsTimestampStart": 1774531800, "earningsTimestampEnd": 1774531800, "earningsCallTimestampStart": 1774512000, "earningsCallTimestampEnd": 1774512000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.65, "epsForward": -0.606, "epsCurrentYear": -0.64467, "priceEpsCurrentYear": -2.5129135, "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "messageBoardId": "finmb_426137", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -4.14201, "regularMarketPrice": 1.62, "corporateActions": [], "regularMarketTime": 1771621202, "exchange": "NMS", "fiftyDayAverageChange": -0.16517997, "fiftyDayAverageChangePercent": -0.09252847, "twoHundredDayAverageChange": -0.34227502, "twoHundredDayAverageChangePercent": -0.17442764, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "marketState": "CLOSED", "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]